R&D channel feed

Chiesi picks a pipeline fight with No­var­tis, go­ing head-to-head on a big new tar­get for asth­ma

9 years ago

Acor­da writes off an­oth­er R&D pro­gram as Ampyra flops in stroke study

9 years ago

MD An­der­son to biotech bil­lion­aire Soon-Sh­iong: Get your own slo­gan. ‘Moon Shots’ be­longs to us

9 years ago

Gilead punts hep B drug as GlobeIm­mune joins the (dead qui­et) ranks of zom­bie biotechs

9 years ago

Spec­trum floats new PhI­II idea af­ter FDA slaps down failed blad­der can­cer drug

9 years ago

J&J takes one of its top block­buster prospects to the FDA, in search of a big ap­proval

9 years ago

Fledg­ling biotech Syn­tim­mune looks to take flight in the clin­ic with a new CEO and a slight­ly less vir­tu­al busi­ness mod­el

9 years ago

No ear­ly suc­cess for Re­gen­eron, Sanofi in PhI­II out­comes study for PC­SK9 drug Pralu­ent

9 years ago

Grunen­thal snags a PhI­II-ready or­phan drug in Thar Phar­ma buy­out

9 years ago

Am­gen, No­var­tis are rac­ing to reg­u­la­tors with pos­i­tive PhI­II mi­graine da­ta, but ri­vals are in hot pur­suit

9 years ago

Es­ca­lat­ing R&D woes spur fresh M&A chat­ter for cash-rich Gilead

9 years ago

Two years in­to an R&D over­haul, GSK plans $250M lab project near Philly for an­oth­er mi­gra­tion of US staffers

9 years ago

Is Am­gen still shoot­ing blanks in its war with pay­ers over Repatha re­im­burse­ment?

9 years ago

Med­i­cines Co, Al­ny­lam gen­er­ate pos­i­tive buzz with ev­i­dence of a durable, 6-month LDL re­sponse to PC­SK9 ri­val

9 years ago

The Park­er In­sti­tute aims to speed up can­cer R&D, carv­ing out du­pli­cate IRBs at top cen­ters

9 years ago

Roche har­ness­es a net­work of aca­d­e­m­ic I/O re­searchers in $100M glob­al col­lab­o­ra­tive

9 years ago

Ab­b­Vie, Enan­ta hep C com­bo looks stel­lar in CKD study as ri­vals hus­tle along the lat­est cures

9 years ago
Pharma

Strug­gling gene ther­a­py pi­o­neer uniQure brings out the ax, chop­ping pro­grams and staffers in over­haul

9 years ago

Promis­ing or in­con­clu­sive? Gilead fields PhII GS-4997 da­ta, trig­ger­ing more push­back on NASH claims

9 years ago

Puma shares ripped af­ter grow­ing grade 3 di­ar­rhea threat is high­light­ed in an ab­stract

9 years ago

Did Mer­ck KGaA’s ag­ing at­aci­cept just fail a PhI­Ib lu­pus tri­al? Well, yes, but…

9 years ago

Step 3: Sanofi com­mits up to $100M to opt-in on Al­ny­lam’s PhI­II RNAi he­mo­phil­ia tri­al

9 years ago

Dy­navax shares crater af­ter the FDA re­jects Hep­lisav-B, again, and CEO sig­nals for help

9 years ago

Un­der a short as­sault, Cor­bus coun­ter­at­tacks with pos­i­tive PhII da­ta for sys­temic scle­ro­sis drug

9 years ago
First page Previous page 310311312313314315316 Next page Last page
A service from the Financial Times